

CLAIM AMENDMENTS

1-47. (canceled)

48. (currently amended): A method to identify an agent that decreases 101P3A11 protein activity, comprising:

providing a first sample of cells and a second sample of cells, wherein the cells of each sample express 101P3A11 (~~SEQ ID NO:2866~~);

contacting the first sample with a candidate compound and

~~observing~~ measuring 101P3A11 protein activity in the first sample with the candidate compound;

~~observing~~ measuring 101P3A11 protein activity in the second sample, wherein the second sample has not been contacted with said candidate compound;

comparing the ~~observed~~ measured 101P3A11 protein activity in said first and second samples;

whereby a diminution in the 101P3A11 protein activity in said first sample as compared to said second sample identifies said compound as an agent that decreases 101P3A11 protein activity;

wherein 101P3A11 protein is SEQ ID NO: 2866; and

wherein said activity comprises 101P3A11-mediated cAMP accumulation or the downstream signaling effects thereof.

49. (canceled)

50. (previously presented): The method of claim 48, wherein said cells have been modified to contain an expression system for said 101P3A11 protein.

51-53. (canceled)

54. (previously presented): The method of claim 48, wherein the candidate compound is an antibody that binds specifically to the 101P3A11 protein.

55. (currently amended): The method of claim 48, wherein measuring the 101P3A11 activity comprises measuring a downstream signaling effect which is 101P3A11-mediated ERK phosphorylation.

56. (canceled)